SCHEMBL14754342

SCHEMBL14754342

Fc1ncccc1-c1cscn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP6 P55212 1/20 0.48
IDO1 P14902 5/20 0.43
TDO2 P48775 3/20 0.43
MAPT P10636 4/20 0.40
SCN9A Q15858 1/20 0.38
F2RL1 P55085 1/20 0.38
METAP2 P50579 2/20 0.36
METAP1 P53582 2/20 0.36
NPC1 O15118 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
CYP2D6 P10635 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36
RAB9A P51151 1/20 0.36
FKBP1A P62942 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21091024 0.81 CASP6 (0.45) CASP6IDO1TDO2SCN9AF2RL1
SCHEMBL4533718 0.78 CASP6 (0.45) CASP6IDO1TDO2MAPTSCN9A
SCHEMBL10151023 0.77 MPL (0.50) CASP6IDO1TDO2MAPTSCN9A
SCHEMBL5004510 0.74 IDO1 (0.43) CASP6IDO1TDO2METAP2METAP1
SCHEMBL27928104 0.74 SCN9A (0.41) CASP6IDO1TDO2SCN9AF2RL1
SCHEMBL26259974 0.74 SCN9A (0.43) CASP6IDO1TDO2SCN9AMETAP2
SCHEMBL7638480 0.73 CYP11B2 (0.35) CASP6MAPTNPC1KDM4ECYP3A4
SCHEMBL2512862 0.73 KDM4A (0.49) CASP6IDO1TDO2MAPTKDM4E
SCHEMBL3913894 0.72 KDM4E (0.54) CASP6TDO2MAPTMETAP1NPC1
SCHEMBL17626069 0.71 MAPT (0.38) MAPTNPC1CYP11B2NAPRT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170309-B1 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL HYDRA BIOSCIENCES INC (US) 2016-10-26 EP disclosed
US-20130165427-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES HYDRA BIOSCIENCES, INC. (US) 2013-06-27 US disclosed
US-20130059869-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS HYDRA BIOSCIENCES, INC. 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165427-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELANE, CASP3, MMP8 CASP6 83/4885IDO1 3851/4885TDO2 3806/4885
US-20130059869-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS TRPA1, TRPV1, TRPV3 CASP6 1461/4885IDO1 2838/4885TDO2 1850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.